🇧🇷Brazil

Atraso Operacional por Registro Manual no SNGPC (Sistema Nacional de Gerenciamento de Produtos Controlados)

3 verified sources

Definition

SNGPC requires real-time reporting of all controlled-substance movements. Manual workflows involve: (1) receive prescription; (2) verify prescriber & patient details; (3) manually enter drug/quantity/dosage into SNGPC; (4) cross-check against inventory; (5) update physical stock. Each step introduces delay and re-work loops if data mismatches occur.

Key Findings

  • Financial Impact: LOGIC-based estimate: 2–5 minutes per controlled-substance transaction × 20–50 controlled transactions/day per pharmacy × 22 working days/month = 14.6–110 hours/month of technician time (R$ 880–R$ 6,600/month at R$ 60/hour blended cost). For pharmacy networks with 50+ locations: R$ 44,000–R$ 330,000/month in lost labor capacity.
  • Frequency: Daily; compounds throughout business hours, especially 11 AM–2 PM and 5 PM–7 PM.
  • Root Cause: SNGPC interface requires manual form completion; no integration with POS (point-of-sale) systems; prescription validation not automated; inventory checks done separately from SNGPC entry.

Why This Matters

The Pitch: Brazilian pharmacy retailers lose 5–15% of controlled-substance transaction capacity due to manual SNGPC entry (estimated 2–5 minutes per transaction). Automated prescription-to-SNGPC integration eliminates manual keying, freeing 30–50 hours/month per pharmacy and increasing counter throughput by 10–20% during peak hours.

Affected Stakeholders

Pharmacy Technician (SNGPC entry), Pharmacist (verification & dispensing), Counter Staff (queuing customers)

Deep Analysis (Premium)

Financial Impact

Financial data and detailed analysis available with full access. Unlock to see exact figures, evidence sources, and actionable insights.

Unlock to reveal

Current Workarounds

Financial data and detailed analysis available with full access. Unlock to see exact figures, evidence sources, and actionable insights.

Unlock to reveal

Get Solutions for This Problem

Full report with actionable solutions

$99$39
  • Solutions for this specific pain
  • Solutions for all 15 industry pains
  • Where to find first clients
  • Pricing & launch costs
Get Solutions Report

Methodology & Sources

Data collected via OSINT from regulatory filings, industry audits, and verified case studies.

Evidence Sources:

Related Business Risks

Penalidades por Não-Conformidade ao SNGPC (Portaria 344/1998)

LOGIC-based estimate: Typical ANVISA administrative fines for non-compliance range R$ 5,000–R$ 50,000 per violation; larger networks face R$ 100,000+ for systemic SNGPC failures. Operational costs from license suspensions or revocation: loss of controlled-substance revenue (15–30% of pharmacy revenue), estimated R$ 50,000–R$ 500,000+ per pharmacy per month during suspension.

Risco de Desvio e Furto de Medicamentos Controlados por Falta de Rastreabilidade em Tempo Real

LOGIC-based estimate: Average shrinkage rate 1–3% of controlled-substance inventory. For a mid-sized pharmacy (R$ 100,000/month in controlled-substance revenue): R$ 1,000–R$ 3,000/month loss. For pharmacy network (50 locations): R$ 50,000–R$ 150,000/month undetected shrinkage. Annual impact: R$ 600,000–R$ 1.8M per network.

Erros de Decisão por Falta de Visibilidade em Tempo Real sobre Estoque de Medicamentos Controlados

LOGIC-based estimate: 2–5% inventory waste (expiration/spoilage) on R$ 100,000/month controlled-substance revenue = R$ 2,000–R$ 5,000/month. 5–10% stock-out-driven lost sales = R$ 5,000–R$ 10,000/month forgone margin. Combined: R$ 7,000–R$ 15,000/month per pharmacy. Network (50 locations): R$ 350,000–R$ 750,000/month. Annual: R$ 4.2M–R$ 9M.

Multa por Violação de LGPD e Privacidade do Consumidor

R$ 8,497,500.00 (confirmed fine); potential industry exposure: R$ 50,000–R$ 3,000,000 per administrative proceeding depending on scale and intent.

Risco de Recusa de Cobertura de Plano de Saúde por Violação de Dados Sensíveis

Per-customer litigation cost: R$ 10,000–R$ 50,000; churn impact: 2–5% customer base loss annually; class action risk: R$ 5,000,000+.

Perda por Vencimento de Medicamentos (Product Expiration Waste)

Estimated: R$ 2,000–25,000 annually per pharmacy (2–5% of typical inventory value of R$ 100,000–500,000). Pharmacy chains with 10+ locations: R$ 20,000–250,000+ annually.

Request Deep Analysis

🇧🇷 Be first to access this market's intelligence